NEVVI Medicare utilization intelligence
or

← back

Provider profile

MERCHANT, NOOR M.D.

Hematology-Oncology · NPI 1346227352 · SEBASTIAN, FL

1
Groups
80
Codes · 2024
287,145
Disclosed services

MERCHANT, NOOR is a Hematology-Oncology in SEBASTIAN, FL, a member of 1 medical group, who billed 80 distinct codes to Medicare Part B in 2024.

Groups: FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC (FORT MYERS, FL)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

287,145
disclosed services
80
codes billed to Medicare Part B
Prior year · CY2023 226,310 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
J9271 Injection, pembrolizumab, 1 mg
J9263 Injection, oxaliplatin, 0.5 mg
J9299 Injection, nivolumab, 1 mg
J0185 Injection, aprepitant, 1 mg
J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J1434 Injection, fosaprepitant (focinvez), 1 mg
J0897 Injection, denosumab, 1 mg
J9267 Injection, paclitaxel, 1 mg
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
J1306 Injection, inclisiran, 1 mg
J1437 Injection, ferric derisomaltose, 10 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
Q5129 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg
J1756 Injection, iron sucrose, 1 mg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
36415 Insertion of needle into vein for collection of blood sample
J0461 Injection, atropine sulfate, 0.01 mg
J2469 Injection, palonosetron hcl, 25 mcg
J0640 Injection, leucovorin calcium, per 50 mg
96372 Injection of drug or substance under skin or into muscle
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml
J9190 Injection, fluorouracil, 500 mg
J2405 Injection, ondansetron hydrochloride, per 1 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J2919 Injection, methylprednisolone sodium succinate, 5 mg
96375 Injection of additional new drug or substance into vein
J9395 Injection, fulvestrant, 25 mg
J9206 Injection, irinotecan, 20 mg
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
96413 Administration of chemotherapy into vein, 1 hour or less
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
Q5127 Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg
85045 Red blood count, automated test
J9045 Injection, carboplatin, 50 mg
J1200 Injection, diphenhydramine hcl, up to 50 mg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
J9196 Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to j9201, 200 mg
96415 Administration of chemotherapy into vein, each additional hour
81003 Automated urinalysis test
96417 Administration of additional new drug or substance into vein, 1 hour or less
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
J3489 Injection, zoledronic acid, 1 mg
J7030 Infusion, normal saline solution , 1000 cc
J3475 Injection, magnesium sulfate, per 500 mg
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96360 Infusion into a vein for hydration, 31-60 minutes
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
76770 Complete ultrasound scan behind abdominal cavity
96374 Injection of drug or substance into vein
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
96411 Administration of additional new drug or substance into vein using push technique
J1954 Injection, leuprolide acetate for depot suspension (cipla), 7.5 mg
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99195 Drawing of blood for a medical problem
96361 Infusion into a vein for hydration, each additional hour
76857 Limited ultrasound scan of pelvis
99203 New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
99231 Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
99211 Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional
76872 Ultrasound scan of pelvic region through rectum
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96409 Administration of chemotherapy into vein using push technique
99212 Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more
38222 Biopsy and aspiration of bone marrow sample for diagnosis
74178 Ct scan of abdomen and pelvis before and after contrast
76377 3d radiographic procedure with computerized image postprocessing
99496 Transitional care management services for problem of high complexity

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.